DALDA: Physiology and What Research Reports

What DALDA Is

DALDA is an acronym for a synthetic tetrapeptide, H-Tyr-D-Arg-Phe-Lys-NH₂, built from four amino-acid residues, one of which (D-arginine) is a mirror-image D-amino acid rather than the L-form used in ordinary proteins. It belongs to a family of laboratory-designed opioid peptides rather than to the body's own peptide systems: DALDA is not synthesised by any human tissue, has no endogenous receptor role of its own, and exists only because chemists made it. Its best-known relative is [Dmt¹]DALDA, in which the N-terminal tyrosine is replaced by 2',6'-dimethyltyrosine (Dmt), a modification that changed the peptide's behaviour at the receptor substantially in published characterisations (PMID 11860345).

Readers usually encounter the term in one of three places: medicinal-chemistry papers on opioid peptide design, computational modelling of the mu-opioid receptor, or preclinical pain-research literature. This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about health, symptoms or treatment.

Where It Acts in the Body: Mu-Opioid Receptor Physiology

To understand DALDA it helps to understand the system it was designed to probe. The mu-opioid receptor (MOR) is a G-protein-coupled receptor expressed on neurons in the spinal cord dorsal horn, brainstem, thalamus and limbic regions, and also on some peripheral sensory terminals and immune cells. Endogenous peptides such as beta-endorphin and the enkephalins bind it; so do morphine and related alkaloids. Activation typically reduces neuronal excitability and dampens the transmission of nociceptive (pain) signals, while also producing the well-documented respiratory, gastrointestinal and reward-related effects of opioid agonists.

DALDA was constructed as a chemical tool to interrogate that receptor with a short, highly polar, positively charged peptide instead of a small lipophilic alkaloid. The physiological question behind that design was whether a peptide could be made selective enough, and stable enough, to activate MOR cleanly in experimental systems. Published analogue series addressed exactly that question by systematically altering the four residues and measuring the resulting opioid activity profiles in vitro (PMID 11121615).

How DALDA Is Studied and Measured

Because DALDA is a research chemical rather than a circulating hormone, it is not "measured" in patients the way vitamin D or testosterone is. Instead, the literature characterises it with four broad approaches:

• Radioligand binding and functional bioassays. Researchers measured affinity for mu, delta and kappa receptors and functional potency in isolated tissue preparations, generating the in vitro opioid activity profiles that define an analogue series (PMID 11121615).
• Selectivity and tolerance comparisons. A review-level characterisation described [Dmt¹]DALDA as highly selective and potent at mu-opioid receptors, and reported that it was not cross-tolerant with systemic morphine (PMID 11860345).
• Computational modelling. A 2020 study examined how DALDA, [Dmt¹]DALDA and the related compound KGOP01 bind to the mu-opioid receptor, building a mechanistic picture of the peptide–receptor interaction at the molecular level (PMID 32365707).
• Fluorescent labelling. Because peptides can be tagged and visualised, one study incorporated fluorescent probes into [Dmt]DALDA and reported that both the type and the location of the probe affected potency, receptor selectivity and intrinsic efficacy (PMID 15885115).

Animal pain models

In vivo work has focused on spinal delivery. The study of intrathecal DALDA peptides characterised antinociceptive effects following bolus intrathecal administration, an approach that places the peptide directly into the cerebrospinal fluid surrounding the spinal cord rather than relying on systemic distribution (PMID 30367811). Route matters here: highly charged peptides like DALDA are poorly suited to crossing membranes passively, which is one reason the experimental literature leans on direct central routes.

What the Literature Reports

Tolerability and Adverse Effects: What Studies Report

The verified literature summarised here is preclinical and chemical in nature, and it does not establish a human safety profile for DALDA or its analogues. The most safety-relevant observation in this set is pharmacological rather than clinical: researchers reported that [Dmt¹]DALDA was not cross-tolerant with systemic morphine, an observation about how repeated opioid exposure changes responsiveness rather than a statement about harm (PMID 11860345). Beyond that, no controlled human adverse-event data appear in these papers.

Interpreting that gap conservatively matters, because DALDA is a mu-opioid receptor agonist by design (PMID 32365707). The class effects associated with mu-opioid agonism — respiratory depression, sedation, constipation, dependence — are the reason opioid compounds are tightly regulated and are studied under medical supervision. Nothing in the cited work suggests DALDA is exempt from those class considerations, and nothing in it characterises them for this peptide.

Why the Term Matters to Peptide Readers

DALDA is frequently mentioned as a structural ancestor in discussions of small cationic tetrapeptides, and the Dmt-containing chemistry that made [Dmt¹]DALDA potent at MOR (PMID 11860345) reappears in later peptide design work. Readers who meet the name in a forum post or an ingredient list are usually meeting a research chemical, not a therapeutic. In the United States, compounds of this kind are handled as research-use-only materials; they are not FDA-approved drugs and are not dietary supplements.

Limitations of the Evidence

1. All cited findings come from in vitro assays, computational models or animal experiments — none are human clinical trials.
2. Chemical modification changed pharmacology substantially in this series, so results for one analogue do not transfer to another; even attaching a fluorescent tag altered potency and selectivity (PMID 15885115).
3. Effects reported after direct intrathecal delivery (PMID 30367811) cannot be assumed to occur by other routes.
4. Long-term outcome, dependence and safety data are absent from this evidence base.

References

• Synthesis and in vitro opioid activity profiles of DALDA analogues (European Journal of Medicinal Chemistry, 2000)
• [Dmt(1)]DALDA is highly selective and potent at mu opioid receptors, but is not cross-tolerant with systemic morphine (Current Medicinal Chemistry, 2002)
• Type and location of fluorescent probes incorporated into the potent mu-opioid peptide [Dmt]DALDA affect potency, receptor selectivity and intrinsic efficacy (The Journal of Peptide Research, 2005)
• Characterization of the antinociceptive effects of intrathecal DALDA peptides following bolus intrathecal delivery (Scandinavian Journal of Pain, 2019)
• Mechanistic Understanding of Peptide Analogues, DALDA, [Dmt(1)]DALDA, and KGOP01, Binding to the mu Opioid Receptor (Molecules, 2020)